B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy

Nunzia Migliaccio1, Camillo Palmieri2, Immacolata Ruggiero1, Giuseppe Fiume2, Nicola M Martucci1, Iris Scala1, Ileana Quinto2, Giuseppe Scala2*, Annalisa Lamberti1 and Paolo Arcari1,3*

Abstract

**Background:** Despite the clinical response of conventional anticancer therapy, including chemotherapeutic treatments, radiation therapy and corticosteroids, tumorigenic B-cell lymphomas show an incomplete response to clinical practices that result in a minimal residual disease (MRD) where few residual neoplastic cells undetected in vivo, replenish the cancer cell reservoir. This scenario, which is also shared with other cancer diseases, requires the development of strategies to advance in novel, selective targeting toward the tumorigenic cells that survive to the anticancer agents.

**Methods:** Here, we have taken advantage of the therapeutic properties of an idiotype specific peptide (pA20-36) that bind specifically to murine B-lymphoma cells in the setting of an anti cancer strategy, based on the selected delivery of electrostatic-based complex, peptide-siRNA. To this end, two engineered, arginine rich, peptides that included the pA20-36 targeting sequence were designed to bind fluorescent-labelled siRNA. One peptide presented 9 Arg at the C-terminal of pA20-36 whereas the other included 5 Arg at the N- and C-terminus, respectively.

**Results:** Compared to the control and random peptide-siRNA complexes, both pA20-36-siRNA complexes were endowed with the selective delivering of fluorescent-labelled siRNA toward the A20 murine B-cell lymphoma, as evaluated by cytofluorimetry and confocal microscopy, whereas fluorescent-labelled siRNA alone was not internalized in the selected cells. Compared to peptide controls, the use of the modified pA20-36 peptides complexed with siRNA anti-GAPDH and anti-Bcl2 showed a down-regulation in the expression levels of the corresponding genes.

**Conclusions:** Peptide-siRNA complex can be suitable tool for both selective peptide-driven cell targeting and gene silencing. In this setting, the improvement of this strategy is expected to provide a safe and non-invasive approach for the delivery of therapeutic molecules.

**Keywords:** Id-peptide, Peptide-siRNA complex, Peptide engineering, B lymphoma cells, Minimal residual disease (MRD)

Background

The targeted delivery of siRNA has recently emerged as a powerful therapeutic tool in different diseases, including cancer [1]. A major requirement for the targeted delivery of therapeutic siRNA in cancer concerns the specificity for target cells, meaning that the delivery systems must be highly specific for the tumor cells and not able to exhibit the toxic effects of its cargo in normal cells. This issue may be fulfilled by targeting ligands for cell receptors to deliver siRNA to specific cell and/or tissue types. Commonly used targeting ligands include aptamers, cell penetrating peptides, antibodies, peptides or proteins, and small molecule ligands [2-5].

Peptides are the most promising tools for siRNA delivery, as they may fulfill different major requirements for an efficient siRNA delivery, including siRNA attachment, receptor recognition, disruption of endosomal membrane and intracellular trafficking [6-8]. Up to now a number of peptide ligands has been used to successfully deliver siRNA into target cells, with improvement of bio-available and specific delivery of nucleic acids to target cells [9].

The idiotype determinants of the immunoglobulin B-cell Receptor (Ig-BCR) of B cell malignancies are unique for a given clonal population and function as specific tumor antigen that may be exploited for targeted therapies. In the last
years, we identified idotype-specific peptides for the Ig-BCR of B cell tumors, named “Id-peptides”, that showed the following properties: a) binding to tumor target cells with high specificity and sensitivity, both in vitro and in vivo; b) internalization into target tumor cells by a BCR-mediated endocytosis; c) specific delivering of a cargo protein into target tumor cells [10,11]. Therefore, we used the specific identified peptide endowed with high-affinity toward highly aggressive murine A20 lymphoma cells [12-14]. Here we addressed the relevance of Id-peptides as carriers for the specific delivery of siRNA to target neoplastic B cells.

**Results**

**Peptide-siRNA complexes cellular uptake**

The Id-peptide pA20-36 is a specific binder for the surface Ig-BCR of A20 B-cell lymphoma cells. With the aim of evaluating the Id-peptide for the specific delivery of siRNA to target neoplastic B cells, we designed two new peptides, each composed of two modules: a N-terminal region corresponding to the original pA20-36 sequence targeting the Ig-BCR of the A20 B cells and a C-terminal or C- and N-terminal stretch of basic amino acids (Arginine) that promotes the formation of electrostatic based siRNA-peptide complexes [15]. The 5R-A20-36-5R peptide contained two additional stretches of 5 arginine residues flanking the pA20-36 sequence whereas the pA20-36-9R contained an additional stretches of 9 arginine residues at the C-terminal region of the pA20-36 sequence. Both constructs contained D-Arg at the extremity and the substitution of L-arginine for the enantiomeric D-arginine was made for protease protection [16].

These peptides were complexed with fluorescent-labelled control siGLORNAi and tested for their ability to drive the selective internalization of the siRNA in A20 cells. As reported in Figure 1, the cytofluorimetric evaluation of the red fluorescence indicated that compared to untreated cells (Figure 1A and B, sample 0) or to cells treated at zero time, that showed fluorescent values similar to those of untreated samples (not shown), both peptide-siRNA complexes were able to delivery siRNA in A20 cells with respect to the corresponding control peptide-siRNA complexes. In particular, with respect to A20-36-9R-siGLORNAi, 5R-A20-36-5R-siGLORNAi appeared to be more efficient. This result was obtained by the cytofluorimetric analysis of permeabilized A20 cells from two independent experiments (Figure 1A and B, samples 2 and 3). The same effect was not observed with the control random peptides and with the non-modified A20-36-siRNA (Figure 1A and B, samples 4, 5 and 6).

**Confocal microscopy of peptide-siRNA complexes cellular uptake**

To highlight the A20 BCR-mediated internalization of the peptide-siRNA, we analyzed the localization of various complexes using confocal microscopy. As reported in Figure 2, compared to untreated A20 cells (Figure 2A, upper row), fluorescent siGLORNAi alone was not able to enter A20 cells since no fluorescence at 570 nm was detectable (Figure 2A, middle row, negative control). Moreover, no fluorescence at 570 nm was detectable when A20 cells were transfected with siGLORNAi by using Lipofectamine (Figure 2A, lower row). When the
Figure 2 (See legend on next page.)
cells were treated with siGLORNAi complexed with A20-36-9R or 5R-A20-36-5R peptides, a red fluorescent signal was instead detected (Figure 2B and C, upper and middle rows) whereas treatment of the A20 cells with siGLORNAi complexed with the random peptides (RND-9R and 5R-RND-5R) did not show any siRNA internalization (Figure 2B and C, lower rows).

Effect of siRNAGAPDH-peptide and siRNABcl2-peptide complexes on gene silencing

In order to evaluate the capability of the complex to decrease the levels of GAPDH mRNA, we used the same peptides complexed to siRNA directed against GAPDH mRNA (siRNAGAPDH). As controls, we first analysed the efficiency of siRNA anti-GAPDH to silence GAPDH expression in NIH/3T3 and in A20 cells by using lipofectamine (Figure 3). Compared to basal expression of GAPDH, siRNAGAPDH was able to downregulate in NIH/3 T3 cells the level of the enzyme of about 40% after 30 hours from transfection using both 100 or 250 pmoles of siRNAGAPDH whereas in A20 cells, GAPDH silencing was instead of about 10% after 72 hours from transfection using 100 pmoles of siRNAGAPDH. Treatment of A20 cells with peptide-siRNAGAPDH complex resulted instead relatively more efficient compared to lipofectamine (Figure 4). In fact, the A20-36-9R-siRNA-GAPDH and 5R-A20-36-5R-siRNAGAPDH complexes were able to decrease the expression levels of GAPDH after 48 hours of about 15% and 25% lower respectively, thus confirming what observed by cytofluorimetry. To ascertain if the observed reduction occurred also at transcription level, qRT-PCR was settled on RNA samples prepared from A20 cells after their treatment with A20-36-9R-siRNA-GAPDH in the same experimental conditions. As reported in Figure 5, compared to β-actin as control, a reduction of about 38% of GAPDH mRNA was detected. To confirm this behaviour, we then applied this strategy to silence the anti-apoptotic expression of Bcl2, highly expressed in lymphoma cells [17]. As shown in Figure 6, compared to controls, treatment of A20 cells with 5R-A20-36-5R-siRNABcl2 resulted in a reduction of Bcl2 mRNA of about 45%.

**Figure 2** Confocal microscopy of A20 cells after treatment with labeled siGLORNAi and peptide-siGLORNAi. A20 cells were incubated with siGLORNAi for 4 hours. After 3 washes, cells were analyzed at confocal microscopy. (A) Upper row: untreated A20 cells. Middle row: A20 cells after treatment with siGLORNAi alone. Lower row: A20 cells transfected with siGLORNAi by using Lipofectamine 2000. Peptide-siGLORNAi complexes were incubated with A20 cells for 4 hours and after 3 washes, cells were analysed at confocal microscopy. (B) Upper row and Middle row: images at low and high magnification, respectively of A20 cells treated with A20-36-9R-siGLORNAi. Lower row: A20 cells treated with 5R-A20-36-5R-siGLORNAi. (C) Upper row and Middle row: images at low and high magnification, respectively of A20 cells treated with 5R-RND-5R-siGLORNAi. Lower row: A20 cells treated with 5R-RND-5R-siGLORNAi.

**Figure 3** Down-regulation of GAPDH expression in NIH/3T3 and A20 cells. siRNAGAPDH was transfected with Lipofectamine 2000 at 37°C for 30 and 72 hours in (A) NIH/3T3 and (B) A20 cells. After incubation, cells extracts were analysed by western blot with anti-GAPDH antibody. (A) Lanes: C, untreated cells; 1 and 2 cells treated for 30 hours with 100 and 250 pmoles of siRNAGAPDH, respectively; 3 and 4, cells treated for 72 hours with 100 and 250 pmoles of siRNAGAPDH, respectively. (B) Lanes: C, untreated cells; 1 and 2 cells treated for 30 hours with 100 pmoles of siRNA-GAPDH and siRNASC, respectively; 3 and 4, cells treated for 72 hours with 100 pmoles of siRNAGAPDH and siRNASC, respectively. Data from three experiments are reported as the mean ± SD. * p < 0.05 compared to control.
Discussion

In this work we report a non-covalent peptide-based strategy for the delivery of molecules into cultured cancer cells using the capability of peptide to form stable electrostatic complex with siRNA. We have taken advantage from a previous work where we have reported the targeting specificity and the therapeutic properties of an idiotype-specific peptide toward a murine B lymphoma engrafted in syngenic, immune competent mice [11]. In the mentioned work it was showed that IA20-36 Id-peptide was specifically internalized into target cells with a mechanism of receptor-mediated endocytosis. The A20-36 Id-peptide triggered a BCR-mediated signaling that induced apoptosis of the target cells. Two different engineered peptides containing the sequence of the A20-36 Id-peptide recognized by BCR were designed. One contained five additional arginines at both N- and C-terminus of the Id-peptide sequence the other contained nine arginines only at the C-terminus. These peptides, besides containing the sequence for selective B cells recognition, were also able to make stable electrostatic complex with negatively charged siRNA [18,19] (Figure 7). Using a commercially available fluorescent control siRNA these complexes were able to selectively recognize the murine A20 cells for siRNA delivery as evaluated by cytofluorimetric measurements at 570 nm. The additional confocal microscopy also highlighted the internalization of siRNA and this was specifically driven by A20-36 peptide since no internalization was observed using random peptides.

The selectivity of the siRNA peptide complexes relies on the ability of the pA20-36 peptide to target only the idiotypic determinants of the immunoglobulin receptor displayed on A20 B cells, and not of other immunoglobulin receptors or different cell surface receptors. In fact, pA20-36 peptide does not bind to the entire normal mouse PBMC and bone marrow cells, as well other B cell tumor

---

**Figure 4** Effect of siRNAGAPDH on the expression levels of GAPDH. A20 cells were treated with siRNAGAPDH and peptide-siRNAGAPDH complexes for 48 hours. After incubation cell extracts were analyzed by western blot with anti-GAPDH antibody. A. Lanes: 1, control; 2, siRNAGAPDH; 3, siRNASCN; 4, A20-36-9R; 5, A20-36-9R-siRNAGAPDH; 6, A20-36-9R-siRNASCN; 7, SR-A20-36-SR; 8, SR-A20-36-9R-siRNAGAPDH; 9, SR-A20-36-9R-siRNASCN. B. Lanes: 1, Control; 2, RND-9R; 3, RND-9R-siRNAGAPDH; 4, RND-9R-siRNASCN; 5, SR-RND-SR; 6, SR-RND-9R-siRNAGAPDH; 7, SR-RND-9R-siRNASCN. Data are from three experiments are reported as the mean ± SD. * p < 0.05 compared to control and to all other samples.

**Figure 5** Effect of siRNAGAPDH on the expression levels of GAPDH mRNA. $5 \times 10^5$ A20 cells were treated with A20-36-9R peptide in absence (control) or presence of siRNAGAPDH. 48 hours post-treatment, total RNA was extracted and analysed by qRT-PCR to evaluate the GAPDH mRNA expression relative to β-actin. A. Lanes: C, control; 1, A20-36-9R; 2, A20-36-9R-siRNAGAPDH; 3, A20-36-9R-siRNASCN. B. Lanes: C, control; 4, RND-9R; 5, RND-9R-siRNAGAPDH; 6, RND-9R-siRNASCN. C. Lanes: C, control; 7, siRNAGAPDH; 8, siRNASCN. Values of mean ± SD (n = 3) are shown.
cell lines (MC3, Raij, 5T33MM) and T cell lines (HPB-ALL, Jurkat) [11]. In fact, as ligand of the idiotypic determinants of the immunoglobulin B-cell Receptor (IgBCR), the specificity of each Id-peptide is strongly restricted to B cell clone (normal or neoplastic) that harbour the cognate IgBCR.

For potential delivery in vitro, we then examined if these peptides were able to deliver siRNAGAPDH by evaluating the expression levels of the corresponding protein in A20 cells. Our results suggest that the both A20-36-9R and 5R-A20-36-5R peptides were able to deliver siRNAGAPDH to B cells and down-regulate the protein expression. To confirm the effective siRNA-mediated gene down-regulation, we also evaluated by qRT-PCR in two separate experiments the mRNA level of GAPDH and Bcl2 using A20-36-9R and 5R-A20-36-5R in complex with siRNAGAPDH and siRNA Bcl2, respectively. Interestingly, the result obtained using 5R-A20-36-5R-siRNABcl2 was more promising compared to that of A20-36-9R-siRNAGAPDH and was in agreement with the finding that 5R-A20-36-5R peptide was more efficient than A20-36-9R (Figure 1). The siRNA internalization strategy here reported should have the great advantage of being based on the specific ligand-receptor interaction. There are several aspects of this approach that can be modified in order to improve its efficacy. Because the lower efficiency of A20-36-9R- and 5R-A20-36-5R-bound to siRNAs was most likely indicative of a lower protection against lysosome degradation, the use of chemically stabilized siRNA may enhance the efficacy on genes down-regulation. Encapsulation of stabilized siRNA entrapped into nanoparticle could greatly enhance half-life and bioavailability [20,21]. Liposomal and polymeric nanoparticles coated with targeting ligands represent one possibility since they have been already employed for delivery [22,23].
Conclusions
In this work, we have exploited a novel method based on the chemistry of siRNA for the construction of stabilized siRNA-peptide complexes for the selective peptide-driven cell targeting and as appropriate tool for effective gene silencing. However, a major limitation of the Id-peptide approach for the specific delivery of siRNA (or other cargos) is the requirement of an Id-peptide selection procedure for each individual B-cell clone (patient). Nevertheless, this concern does not impair the main significance of the present work, which is the proof-of-concept of the specific delivery of a siRNA cargo into target cells accomplished by an Id-peptide.

Materials and methods

Materials
siGLO RISC-Free Control siRNA (siGLORNAi), chemically modified to impair processing and uptake by RISC, one-target plus SMART pool siRNAGAPDH and one-target plus SMART pool siRNABcl2 were from Thermo Scientific Dharmacon (GE Healthcare, CO, USA). Peptide synthesis was performed by CASLO Laboratory, Lyngby, Denmark. Hoechst Stains and Lipofectamine 2000 were from Invitrogen (CA, USA). Cholera Toxin B Subunit FITC Conjugate was from Sigma (MO, USA).

Cell cultures
A20 is a murine cell line derived from a spontaneously arising tumor in an aged BALB/c mouse. It pathologically mimics the characteristics of human diffuse large B cell lymphoma [12]. Cell line was kindly provided by Prof. C. Palmieri (University of Catanzaro, Italy). The cell line was grown in suspension culture with RPMI 1640 medium (GIBCO, CA, USA), supplemented with 10% fetal bovine serum (GIBCO), 50 units/ml penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine at 37 °C in a 5% CO2 atmosphere. NIH/3T3 is a murine embryonic fibroblast cell line. The cell line was provided by CEINGE, Advanced Biotechnologies (Naples, Italy). The cell line was grown in adhesion culture with Dulbecco’s Modified Eagle’s Medium (GIBCO, CA, USA), supplemented with 10% fetal bovine serum (GIBCO), 50 units/ml penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine at 37°C in a 5% CO2 atmosphere.

Cytofluorimetric analysis and confocal microscopy
Target peptides and random peptides (2 μl, 1 mg/ml, 11.58 μM) plus siGLORNAi (4 μl, 25 μM, 100 pmol) were incubated at room temperature for 15 minutes at a 1:10 molar ratio in RPMI without FCS and then added to 50 μl of A20 cells at 20 × 10^6/ml in RPMI 20% FCS. Samples were then incubated at 37°C for 2 hours and 4 hours. After 3 washes in 1× Phosphate Buffered Saline (PBS) (Invitrogen, CA, USA), cells were divided in two aliquots. One aliquot (10^7/ml) was analysed by flow cytometry whereas the other aliquot was suspended in 2 ml of RPMI and incubated in 6 wells plates overnight and then analysed by flow cytometry. Cells before the cytofluorimetric analysis were permeabilized according to the following procedure: cells were resuspended in 100 μl of 1% paraformaldehyde and incubated at room temperature for 1 hour, washed twice with 200 μl 1× PBS, resuspended in 200 μl 1× PBS, 0.1% Triton X-100 (Sigma, MO, USA), 0.1% sodium cyturate and analyzed at flow cytometry.

The following A20 target-specific peptides were designed based on the peptide sequence reported by Palmieri et al., 2010 [11]. 5R-A20-36-5R, (D-Arg)(L-Arg)4-EYVNCNDNLVNCVI-(L-Arg)4(D-Arg); A20-36-9R; EYVNCNDNLVNCVI-(L-Arg)3(D-Arg); whereas as controls the following random peptides were designed: 5R-RND-5R, (D-Arg)(L-Arg)4-SSAYGSKGPSCCSSGVHSI-(L-Arg)4(D-Arg); RND-9R, SSAYGSKGPSCCSSGVHSI(L-Arg)4(D-Arg).

For confocal analysis, after incubation of the cells with complexes peptides-siGLORNAi for 4 hours as above reported, about 10,000 cells were plated on small glass disks in a 24 well dishes and let grown for 12 hours. At different times, disks were removed from the wells, washed three times with 1× PBS, stained with membrane stain Cholera Toxin B Subunit FITC Conjugate whereas cell nuclei were stained with Hoechst 33342 and subsequently observed with a Nikon Confocal Microscope C1 equipped with an EZ-C1 Software for data acquisition. Fluorescent image were collected, upon excitation according to dye manufacturing instructions.

siRNAGAPDH and peptide-siRNAGAPDH complex
siRNAGAPDH was used for GAPDH mRNA down-regulation in NIH/3T3. 100 or 250 pmoles of siRNA-GAPDH were transfected in the presence of Lipofectamine 2000 (Invitrogen, USA) according to manufacturing protocol. Samples were then incubated at 37°C for 30 and 72 hours. After incubation, cell extracts were then analysed by western blot with anti-GAPDH antibody.

A20-36 target peptides and random peptides plus siRNAGAPDH were incubated according the procedure above reported with A20 cells at 20 × 10^6/ml in RPMI 20% FCS. After incubation, cells were suspended in 2 ml of RPMI and incubated in 6 wells plates for 48 and 72 hours. Cell extracts were then analysed by western blot with anti-GAPDH antibody.

Western blotting analysis
Cells were collected, washed twice in 1× PBS and resuspended in 20–40 μl of lysis buffer (50 mM Tris–HCl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 μg/ml aprotinin, leupeptin, pepstatin, 1 mM Na3VO4, 1 mM PMSF) plus a 1× Protease Inhibitors (Sigma). Homogenates were sonicated and centrifuged at 12,000 g for 15 minutes. Equal amounts of protein (30 μg) were resolved on a 10% SDS–PAGE gel and transferred onto nitrocellulose membrane. After blocking the membrane with 5% milk, the membrane was incubated with anti-GAPDH antibody (Sigma, 1:1000) for overnight and then washed with Tris Buffered Saline with 0.1% Tween 20 (TBS-T). After 3 washes, the membrane was incubated with HRP-conjugated goat anti-mouse secondary antibody (1:2000) for 1 hour. The blots were washed again and developed with ECL. The gels were visualized and the bands were quantified by densitometry using Quantity One (Bio-Rad).
1 mM NaF) for 30 min on ice and centrifuged at 14,000 × g for 20 min at 4°C. Protein concentration was determined according to Lowry et al., 1951 [24].

Proteins were separated by SDS-PAGE, electro-transferred to PVDF membrane, and incubated over-night at 4 °C with GAPDH monoclonal antibody at dilution of 1:2000. Anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (Sigma) was used at a dilution of 1:20,000. The specific protein was visualized by an enhanced chemiluminescence detection reagent (SuperSignal West Pico, Molecular Probes, CA, USA), and exposed to X-ray film. All films were analysed by using Image J software 1.46r.

qRT PCR
Total RNA extraction and qRT-PCR were performed as previously described [25]. Briefly, RNA aliquots (500 ng) were reverse transcribed using Random Examers and Superscript III Reverse Transcriptase (Invitrogen), according to the manufacturer’s protocol. qRT-PCR was carried out with the iCycler iQ Real-Time detection system (Bio-Rad Laboratories) under the following conditions: 95°C, 1 min; (94°C, 10s; 60°C, 30s) × 40. Primers were as follows: β-actin, forward 5’-GGCACCCACCTTTCTACATGAG-3’ and reverse 5’-GGAGTCCATCACAATGGCTTG-3’; GAPDH, forward 5’-GTCAGGCAGGATATGGGAAGC-3’ and reverse 5’-AGAAAGGGCCAGATGATGCCACC-3’; Bcl2, forward 5’-TCCAGAAGATGTCCAGTCGC, reverse 5’-CCGGTTCCAGGTACTACGTCACT. GAPDH and Bcl2 expression levels were calculated relative to β-actin mRNA levels as endogenous control by using the formula 2^ΔΔCt sample – ΔΔCt β-actin) [25].

Statistical analysis
Data are reported as average and standard deviation. The statistical significance of differences among groups was evaluated with ANOVA, with the Bonferroni correction as post hoc test, using the software KaleidaGraph v. 4.1. The significance was accepted at the level of p < 0.05.

Abbreviations
FITC: Fluorescein isothiocyanate; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; MRD: Minimal residual disease; PBS: Phosphate buffer saline; PVDF: Polyvinyl difluoride; RND: Random; SCR: Scramble; siRNA: Small interfering RNA.

Competing interests
The authors declare that they have no competing interest.

Authors’ contributions
AL coordinated all the research experiments. CP and GF performed the localization study. NM performed the cytofluorimetric assays. NM and GF performed qRT-PCR. IR and NMM were involved in the peptide analysis and complex formation. IS participated in the expression and localization studies. IR and NMM were involved in the peptide analysis and localization study. NM performed the cytofluorimetric assays. NM and GF coordinated all the research experiments. CP and GF performed the

Acknowledgments
This work was supported by funds from Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (2012CRSPRF_004) to PA, (2012CRSPRF_001) to GS, (2012CRSPRF_002) to IQ. PON Ricerca e Competitività 2007–2013 (PON01_02782) to PA and GS and POR Campania FSE 2007–2013, Project CRÈME.

Author details
1. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy. 2. Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germauro, Catanzaro, Italy. 3. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini, I-80131 Naples, Italy.

Received: 13 March 2014 Accepted: 28 April 2015
Published online: 07 May 2015

References
1. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA Therapeutics: barriers and carriers. AAPS J. 2010;12:492–503.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2007;2:751–60.
3. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, et al. In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 2014;9, e90005.
4. Min K, Song KM, Cho M, Chun YS, Shim YB, Kua JX, et al. Simultaneous electrochemical detection of both PSMA (+) and PSMA (−) prostate cancer cells using an RNA-peptide dual-aptamer probe. Chem Commun. 2010;46(38):5566–8.
5. Bruno JG. A review of therapeutic aptamer conjugates with emphasis on New approaches. Pharmaceuticals. 2013;6:540–7.
6. Martin ME, Rice KG. Peptide-guided gene delivery: AAPS J. 2007;9:E18–29.
7. Rosett Y, Tuschi T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318–29.
8. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541–52.
9. Jäver P, Courisinde T, EL Andaloussi S, Godfrey C, Wood MJ, Gait MJ. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids. 2012;1, e27.
10. De Angelis F, Pujia A, Falcone C, Iaccino E, Palmieri C, Liberale C, et al. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. Nanoscale. 2010;2:2230–6.
11. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboili F, et al. In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotypic-specific peptide binder. Blood. 2010;115:226–38.
12. Kim KJ, Kanellopoulos-Langenin C, Mervin RM, Sachs DH, Aoyagi K. Establishment and characterization of BALB/c lymphoma lines with 5 cell properties. J Immunol. 1979;122:49–54.
13. Glörmchen LH, Kim KJ, Green I, Paul WE. The antigen bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med. 1982;155:445–59.
14. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res. 2006;12:909–15.
15. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release. 2010;143:335–43.
16. Hong SY, Oh JE, Lee KH. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharm. 1999;58:1775–80.
17. Scarfo L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155:36–9.
18. Garcia-Garcia G, Draper DE. Electrostatic interactions in a peptide–RNA complex. J Mol Biol. 2003;331:75–88.
19. Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans. 2007;35:44–6.
20. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 2005;23:1002–7.
21. Rea I, Martucci NM, De Stefano L, Ruggiero I, Terracciano M, Dardano P, et al. Diatomite biosilica nanocarriers for siRNA transport inside cancer cells. Biochim Biophys Acta. 2014;2014:3393–403.

22. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004;8:335–53.

23. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 2005;65:8984–92.

24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–75.

25. Fiume G, Rossi A, de Laurentis A, Falcone C, Pisano A, Vecchio E, et al. Eukaryotic initiation factor 4H is under transcriptional control of p65/NF-κB. PLoS One. 2013;8, e66087.